Sequential therapy for newly diagnosed HER2+ breast cancer that has spread
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a sequence of targeted therapies for people newly diagnosed with HER2-positive breast cancer that has spread to other parts of the body. The goal is to find a treatment plan that can potentially cure the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HER2-positive breast cancer that has spread to distant organs (stage IV) and you have not received any prior treatment for invasive breast cancer.
- You are 18 years or older.
- You are in good physical shape (ECOG performance status 0 or 1).
- Your heart pumps at least 50% of blood out with each beat (LVEF ≥ 50%).
- Your blood counts, liver, and kidney function are within acceptable ranges.
- If you have brain metastases, they must have been treated and stable.
- You are not pregnant and agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
This Phase 3 trial studies different ways of giving common chemotherapy drugs (anthracyclines and taxanes) for locally advanced breast cancer that is HER2-negative. It aims to see which order or “sequencing” may work better for people like you.
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
This study tests whether combining surgery or strong focused radiation with standard treatment can help people whose HER2-positive breast cancer has spread to a few spots (5 or fewer) in the body, but not the brain. It's for patients whose cancer is stable after at least 3 months of first-line therapy.
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.